CA3191160A1 - Microsphere formulations comprising ketamine and methods for making and using the same - Google Patents

Microsphere formulations comprising ketamine and methods for making and using the same

Info

Publication number
CA3191160A1
CA3191160A1 CA3191160A CA3191160A CA3191160A1 CA 3191160 A1 CA3191160 A1 CA 3191160A1 CA 3191160 A CA3191160 A CA 3191160A CA 3191160 A CA3191160 A CA 3191160A CA 3191160 A1 CA3191160 A1 CA 3191160A1
Authority
CA
Canada
Prior art keywords
polymer
microsphere
ketamine
microspheres
polymer microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3191160A
Other languages
English (en)
French (fr)
Inventor
Rachel GALASKA
Kelsey KAHT
Tracy RICHEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakwood Laboratories LLC
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of CA3191160A1 publication Critical patent/CA3191160A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
CA3191160A 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for making and using the same Pending CA3191160A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063067068P 2020-08-18 2020-08-18
US63/067,068 2020-08-18
US202163149911P 2021-02-16 2021-02-16
US63/149,911 2021-02-16
PCT/US2021/046220 WO2022040130A1 (en) 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for making and using the same

Publications (1)

Publication Number Publication Date
CA3191160A1 true CA3191160A1 (en) 2022-02-24

Family

ID=80270269

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3191160A Pending CA3191160A1 (en) 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for making and using the same

Country Status (10)

Country Link
US (1) US12233165B2 (cg-RX-API-DMAC7.html)
EP (1) EP4199917B1 (cg-RX-API-DMAC7.html)
JP (1) JP7814375B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230052915A (cg-RX-API-DMAC7.html)
CN (1) CN115942935B (cg-RX-API-DMAC7.html)
AU (1) AU2021329820A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191160A1 (cg-RX-API-DMAC7.html)
IL (1) IL300547A (cg-RX-API-DMAC7.html)
TW (1) TWI906350B (cg-RX-API-DMAC7.html)
WO (1) WO2022040130A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
EP4611729A1 (en) * 2022-10-31 2025-09-10 Oakwood Laboratories, LLC Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720859B2 (ja) * 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU6510400A (en) * 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
US6479007B1 (en) 1999-09-16 2002-11-12 University Technology Corporation Apparatus and method for controlling pore size in polymeric membranes and thin films
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
WO2002089767A1 (en) * 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050260272A1 (en) 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
EP1996243B1 (en) * 2006-01-11 2014-04-23 HyperBranch Medical Technology, Inc. Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
US20070292521A1 (en) * 2006-06-20 2007-12-20 Schwitzer Co., Ltd Oral Encapsulated Preparation for Aquatic Animals
US20110027331A1 (en) 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
SG11201404038PA (en) * 2012-02-06 2014-08-28 Univ Nanyang Tech Methods of manufacturing core-shell microparticles, and microparticles formed thereof
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP3368553B1 (en) 2015-10-27 2023-08-02 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
SG11202001206YA (en) 2017-09-14 2020-03-30 Agency Science Tech & Res Emulsions, methods and uses thereof
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3968979B1 (en) 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
KR102474965B1 (ko) 2019-07-01 2022-12-07 오크우드 레버러토리즈, 엘엘씨 마이크로스피어 및 에멀션 제조하기 위한 시스템 및 방법
WO2021108801A2 (en) 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists
IL294089B1 (en) 2019-12-20 2026-07-01 Alar Pharmaceuticals Inc Injectable, long-acting formulations of ketamine pamoate salts
US20210361578A1 (en) 2020-04-03 2021-11-25 University Of Iowa Research Foundation Mek1/2 inhibitor-loaded microparticle formulation

Also Published As

Publication number Publication date
IL300547A (en) 2023-04-01
JP2023538901A (ja) 2023-09-12
EP4199917C0 (en) 2026-01-07
EP4199917A4 (en) 2024-10-30
KR20230052915A (ko) 2023-04-20
US12233165B2 (en) 2025-02-25
US20220054420A1 (en) 2022-02-24
EP4199917A1 (en) 2023-06-28
CN115942935B (zh) 2025-09-05
TWI906350B (zh) 2025-12-01
WO2022040130A1 (en) 2022-02-24
CN115942935A (zh) 2023-04-07
JP7814375B2 (ja) 2026-02-16
AU2021329820A1 (en) 2023-03-09
EP4199917B1 (en) 2026-01-07
TW202227044A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
JP6678571B2 (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
US12233165B2 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20160317453A1 (en) High drug load buprenorphine microspheres and method of producing same
US11992559B2 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
US20240342115A1 (en) Microsphere formulations comprising ketamine and methods formaking and using the same
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
ES3061392T3 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20230225993A1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
WO2023133554A2 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20240000772A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
US20240307381A1 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
US20230404922A1 (en) Microsphere formulations comprising btk inhibitors and methods for making and using the same
US20250032451A1 (en) Microsphere formulations comprising asenapine and methods for making and using the same
JP2026507990A (ja) オクトレオチドを含む混合放出プロファイルポリマーミクロスフェア製剤ならびにその製造方法及び使用方法
WO2025117624A1 (en) Microsphere formulations comprising brexpiprazole and methods for making and using the same
WO2024163997A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
JP2024508863A (ja) Btk阻害剤を含むミクロスフェア製剤ならびにその製造方法および使用方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240807

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241102

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250731

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250731

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250731

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250804

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250807

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250807